Information Provided By:
Fly News Breaks for April 17, 2019
RHHBY, IONS
Apr 17, 2019 | 13:50 EDT
Wells Fargo analyst Jim Birchenough reiterated his Outperform rating on Ionis Pharmaceuticals (IONS) following an update today from partner Roche (RHHBY) on its HTT-ASO program for Huntington's disease, stating that he believes the update continues to support potential for accelerated approval filing pending efficacy data that should be updated by year end. When asked during its earnings call about the specific filing strategy of using phase 1 OLE data in comparison to the natural history data, Roche made no comment beyond reiterating that the company will get data, share data with regulators, and work on the fastest way to bring the therapy to patients, said Birchenough. The analyst, who recommends buying Ionis on weakness, added that Roche noted that the company has had initial promising discussion with regulators.
News For IONS;RHHBY From the Last 2 Days
There are no results for your query IONS;RHHBY